Compare PROF & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PROF | SWKH |
|---|---|---|
| Founded | N/A | 1996 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Diversified Financial Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.2M | 175.5M |
| IPO Year | N/A | 1999 |
| Metric | PROF | SWKH |
|---|---|---|
| Price | $6.60 | $17.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $11.00 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 100.8K | 10.3K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 120.89 |
| EPS | N/A | ★ 1.85 |
| Revenue | $14,297,000.00 | ★ $40,149,000.00 |
| Revenue This Year | $64.23 | $52.93 |
| Revenue Next Year | $113.06 | N/A |
| P/E Ratio | ★ N/A | $9.25 |
| Revenue Growth | ★ 67.94 | 62.38 |
| 52 Week Low | $3.76 | $13.17 |
| 52 Week High | $8.36 | $20.49 |
| Indicator | PROF | SWKH |
|---|---|---|
| Relative Strength Index (RSI) | 57.49 | 58.62 |
| Support Level | $6.09 | $16.69 |
| Resistance Level | $7.04 | $17.75 |
| Average True Range (ATR) | 0.42 | 0.31 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 70.27 | 55.24 |
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.